Analysed JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) News Sources
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
30-09-2026
yahoo.com
CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit
06-10-2026
yahoo.com
Ziihera’s FDA Win and Leadership Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ)
16-10-2026
yahoo.com
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
19-10-2026
yahoo.com
Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026
23-10-2026
yahoo.com
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
26-10-2026
yahoo.com
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
27-10-2026
fool.com
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications
30-10-2026
yahoo.com
What is the current price of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)?
The current price of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) is $215.98.
JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) absolute price change since previous trading day?
The absolute price change of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) since the previous trading day is $8.15.
JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) percentage price change since previous trading day?
The percentage price change of JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) since the previous trading day is 3.9215%.
What is the most recent average sentiment score for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)?
The most recent average sentiment score for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)?
The most recent sentiment for JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ) is .
SEC-8K** Filing Available For JAZZ PHARMACEUTICALS PLC (JAZZ:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.